Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that 11 abstracts will be presented at MSVirtual2020, the 8th joint Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) meeting, taking place virtually from September 11 to 13, 2020. The data being presented include two oral presentations of additional findings from the Phase 3 PREVENT study of SOLIRIS (eculizumab) in anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) – one on long-term safety and efficacy data through 192 weeks of treatment with SOLIRIS as monotherapy, and another demonstrating the risk of adjudicated relapse was significantly lower with SOLIRIS than placebo in patients who had previously received rituximab. An additional analysis reinforces the safety of SOLIRIS as a treatment for patients with AQP4 antibody positive NMOSD and for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, based on data from the Phase 3 PREVENT and REGAIN studies and their extensions.

The totality of data being presented at MSVirtual2020 reinforces Alexion’s commitment to conducting research that helps increase awareness and understanding of the burden of disease. Additionally, the data further strengthen the evidence supporting the substantial efficacy and durability of SOLIRIS in reducing relapse risk in patients with AQP4 antibody positive NMOSD and illustrate the benefits of SOLIRIS in decreasing healthcare resource utilization and use of concomitant immunosuppressive therapies (ISTs).

All accepted abstracts are listed below and are now available on the MSVirtual2020 website:

Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder.
Oral: FC01.01 – Sunday, September 13, 2020, 2:00 PM-2:12 PM ET; Free Communications 1

Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT.
Oral: FC01.02 – Sunday, September 13, 2020, 2:12 PM-2:24 PM ET; Free Communications 1

Safety of eculizumab in NMOSD and MG – analysis of the phase 3 studies PREVENT and REGAIN and their extensions
Poster: P0752 – e-Poster presentation

Long-term efficacy and safety of eculizumab in AQP4+ neuromyelitis optica spectrum disorder
Poster: P0727– e-Poster presentation

Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from PREVENT